PTJ
BCAX

Paul Tudor Jones’s Bicara Therapeutics BCAX Stock Holding History

Paul Tudor Jones’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,391
Closed -$461K – 4410
2025
Q4 		$461K Buy
27,391
+8,661
+46% +$148K ﹤0.01% 2763
2025
Q3 		$296K Buy
+18,730
New +$210K ﹤0.01% 2983

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Paul Tudor Jones's BCAX Position: Q1 2026 in Review

Paul Tudor Jones sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 27,391 shares — an estimated $461K sold.

Paul Tudor Jones first reported a position in BCAX in Q3 2025 and held it in 2 quarters. The position peaked at $461K in Q4 2025. 145 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Paul Tudor Jones reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 27,391 Bicara Therapeutics shares in Q1 2026, an estimated $461K.
  • Paul Tudor Jones first reported a position in Bicara Therapeutics in Q3 2025 and held it in 2 quarters.
  • Paul Tudor Jones's Bicara Therapeutics position peaked at $461K in Q4 2025.
  • 145 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.